Pharmaceuticals & Biotech Community
Our community narratives are driven by numbers and valuation.
Pharmaceuticals & Biotech Investing Ideas
Hua Medicine (Shanghai)
56.4% undervalued intrinsic discount
New
Glucose Homeostasis Platform Will Broaden Metabolic Indications And Support Long Runway
View narrativeAN
Published 8 Sep
Ascentage Pharma Group International
54.6% undervalued intrinsic discount
Updated
Takeda Deal And Olverembatinib Trials Will Open Global Markets
View narrativeAN
Updated 9 Sep
Akeso
40.9% undervalued intrinsic discount
9926: Positive Late-Stage Trial Results Will Drive New Market Opportunities
View narrativeAN
Updated 3 Sep
Sichuan Kelun-Biotech Biopharmaceutical
23.3% undervalued intrinsic discount
ADC Expansion And Global Partnerships Will Shape This Biopharma’s Long Term Outlook
View narrativeAN
Updated 3 Sep
Genscript Biotech
6.6% overvalued intrinsic discount
Automation And Global Capacity Will Reshape Biologics Market
View narrativeAN
Updated 3 Sep
WuXi Biologics (Cayman)
7.6% undervalued intrinsic discount
2269: Future Recovery And New Modalities Will Drive Balanced Opportunities And Risks
View narrativeAN
Updated 26 Aug
WuXi Biologics (Cayman)
38.6% undervalued intrinsic discount
Updated
Growing Global Biopharma Demand Will Transform Outsourced Manufacturing
View narrativeAN
Updated 9 Sep
Everest Medicines
32.3% undervalued intrinsic discount
Rising Demand In China And Asia-Pacific Will Expand Biotech Reach
View narrativeAN
Updated 6 Aug
WuXi XDC Cayman
17.2% undervalued intrinsic discount
Backlog Visibility And Complex Bioconjugates Will Support A Stronger Long Term Outlook
View narrativeAN
Published 26 Aug
